New hope for Tough-to-Treat breast cancer: experimental combo enters human trials
NCT ID NCT05383196
Summary
This study is testing whether adding a new, experimental drug called onvansertib to a standard chemotherapy (paclitaxel) is safe and effective for people with triple-negative breast cancer that has spread. The first part finds the safest dose, and the second part checks if the combination can shrink tumors. About 50 participants with this specific, aggressive form of breast cancer will be enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconness Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.